Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAF312 in Polymyositis and Dermatomyositis
NCT01148810Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in polymyositis (PM) and dermatomyositis (DM) comparing BAF312 with Placebo (2 arms). Primary endpoint: Number of Participants Who Responded to BAF312 at 12 weeks. Started Jun 2010; status: terminated.
02
Drugs
siponimod
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT01148810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148810.